Abstract:To reduce time and cost, virtual ligand screening (VLS) often precedes experimental ligand screening in modern drug discovery. Traditionally, high-resolution structure-based docking approaches rely on experimental structures, while ligand-based approaches need known binders to the target protein and only explore their nearby chemical space. In contrast, our structure-based FINDSITEcomb2.0 approach takes advantage of predicted, low-resolution structures and information from ligands that bind distantly related proteins whose binding sites are similar to the target protein. Using a boosted tree regression machine learning framework, we significantly improved FINDSITEcomb2.0 by integrating ligand fragment scores as encoded by molecular fingerprints with the global ligand similarity scores of FINDSITEcomb2.0. The new approach, FRAGSITE, exploits our observation that ligand fragments, e.g., rings, tend to interact with stereochemically conserved protein subpockets that also occur in evolutionarily unrelated proteins. FRAGSITE was benchmarked on the 102 protein DUD-E set, where any template protein whose sequence identify >30% to the target was excluded. Within the top 100 ranked molecules, FRAGSITE improves VLS precision and recall by 14.3 and 18.5%, respectively, relative to FINDSITEcomb2.0. Moreover, the mean top 1% enrichment factor increases from 25.2 to 30.2. On average, both outperform state-of-the-art deep learning-based methods such as AtomNet. On the more challenging unbiased set LIT-PCBA, FRAGSITE also shows better performance than ligand similarity-based and docking approaches such as two-dimensional ECFP4 and Surflex-Dock v.3066. On a subset of 23 targets from DEKOIS 2.0, FRAGSITE shows much better performance than the boosted tree regression-based, vScreenML scoring function. Experimental testing of FRAGSITE's predictions shows that it has more hits and covers a more diverse region of chemical space than FINDSITEcomb2.0. For the two proteins that were experimentally tested, DHFR, a well-studied protein that catalyzes the conversion of dihydrofolate to tetrahydrofolate, and the kinase ACVR1, FRAGSITE identified new small-molecule nanomolar binders. Interestingly, one new binder of DHFR is a kinase inhibitor predicted to bind in a new subpocket. For ACVR1, FRAGSITE identified new molecules that have diverse scaffolds and estimated nanomolar to micromolar affinities. Thus, FRAGSITE shows significant improvement over prior state-of-the-art ligand virtual screening approaches. A web server is freely available for academic users at <a class="extLink" href="http://http:/sites.gatech.edu/cssb/FRAGSITE">http:/sites.gatech.edu/cssb/FRAGSITE</a>.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jcim.0c01160?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jcim.0c01160</a>.Additional information for experimental methods and (Tables S1 and S2) top 40 most frequent fragments in DrugBank drugs and performance of methods for individual DUD-E targets using the modeled target structure (<a class="ext-link" href="/doi/suppl/10.1021/acs.jcim.0c01160/suppl_file/ci0c01160_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Fragmenstein: predicting protein-ligand structures of compounds derived from known crystallographic fragment hits using a strict conserved-binding–based methodology

Streamlining Computational Fragment-Based Drug Discovery Through Evolutionary Optimization Informed by Ligand-Based Virtual Prescreening

Fragment Databases from Screened Ligands for Drug Discovery (FDSL-DD).

Fragment-based Drug Discovery and Molecular Docking in Drug Design.

FRAGSITE: A Fragment-Based Approach for Virtual Ligand Screening

Predicting Fragment Binding Modes Using Customized Lennard-Jones Potentials in Short Molecular Dynamics Simulations

FRAGSITE2: A structure and fragment-based approach for virtual ligand screening

Fragment-Based Ligand Generation Guided By Geometric Deep Learning On Protein-Ligand Structure

Leveraging nonstructural data to predict structures and affinities of protein-ligand complexes

Autoregressive fragment-based diffusion for pocket-aware ligand design

Customised fragments libraries for protein structure prediction based on structural class annotations

Leveraging non-structural data to predict structures of protein–ligand complexes

FragGrow: A Web Server for Structure-Based Drug Design by Fragment Growing within Constraints

Fragment-based screening of enzyme drug targets : Microfluidic mobility shift assay improves confidence in candidate selection

Decision tree-based identification of important molecular fragments for protein-ligand binding

Efficient large-scale exploration of fragment hit progression by exploiting binding-site purification of actives (B-SPA) through combining multi-step array synthesis and HT crystallography.

Improved prediction of ligand-protein binding affinities by meta-modeling

Learning a force field from small-molecule crystal lattice predictions enables consistent sub-Angstrom protein-ligand docking

FMOPhore for hotspot identification and efficient fragment-to-lead growth strategies

Geometric Deep Learning for Structure-Based Ligand Design

In silico Strategies to Support Fragment-to-Lead Optimization in Drug Discovery